Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 20/20 | 1.00 |
| ▸ | INSR | P06213 | 7/20 | 1.00 |
| ▸ | LYN | P07948 | 4/20 | 1.00 |
| ▸ | LCK | P06239 | 4/20 | 1.00 |
| ▸ | KDR | P35968 | 4/20 | 1.00 |
| ▸ | SRC | P12931 | 3/20 | 1.00 |
| ▸ | KIT | P10721 | 3/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 3/20 | 1.00 |
| ▸ | FLT4 | P35916 | 3/20 | 1.00 |
| ▸ | FLT3 | P36888 | 3/20 | 1.00 |
| ▸ | RET | P07949 | 3/20 | 1.00 |
| ▸ | FLT1 | P17948 | 2/20 | 1.00 |
| ▸ | ERBB4 | Q15303 | 2/20 | 1.00 |
| ▸ | ACVR1 | Q04771 | 2/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 2/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 2/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 2/20 | 1.00 |
| ▸ | BTK | Q06187 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1987652 | 1.00 | IGF1R (1.00) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL94862 | 1.00 | IGF1R (1.00) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL1441421 | 1.00 | IGF1R (1.00) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL30631775 | 0.98 | IGF1R (1.00) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL1983472 | 0.98 | IGF1R (1.00) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL95142 | 0.98 | IGF1R (1.00) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL1983470 | 0.98 | IGF1R (1.00) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL29356373 | 0.98 | IGF1R (1.00) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL1985343 | 0.97 | IGF1R (0.98) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL1985751 | 0.97 | IGF1R (0.98) | IGF1RINSRLYNLCKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4561704-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2025-06-04 | — | — | EP | claimed |
| WO-2024026458-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF VERMONT (US) | 2024-02-01 | — | — | WO | claimed |
| EP-4110344-A2 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2023-01-04 | — | — | EP | claimed |
| US-20250263491-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| EP-4561704-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250163159-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20240360243-A1 | ANTIBODIES AGAINST THE ECTODOMAIN OF ERBB3 AND USES THEREOF | ELEVATION ONCOLOGY, INC. | 2024-10-31 | — | — | US | disclosed |
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4364754-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2024026458-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF VERMONT (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20230120736-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230114718-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230077680-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-03-16 | — | — | US | disclosed |
| EP-4110344-A2 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-4104865-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220288221-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2022-09-15 | — | — | US | disclosed |
| US-20220257722-A1 | COMPOSITIONS AND METHODS OF TREATING AND PREVENTING SYSTEMIC COMPLICATIONS OF ACUTE ILLNESS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-08-18 | — | — | US | disclosed |
| US-20220204642-A1 | ANTIBODIES AGAINST THE ECTODOMAIN OF ERBB3 AND USES THEREOF | ELEVATION ONCOLOGY, INC. | 2022-06-30 | — | — | US | disclosed |
| EP-3468996-B1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2022-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288221-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | IGF1R 99/4885INSR 412/4885LYN 243/4885 |
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | IGF1R 177/4885INSR 315/4885LYN 227/4885 |
| US-20230114718-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | IGF1R 177/4885INSR 315/4885LYN 227/4885 |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | IGF1R 177/4885INSR 315/4885LYN 227/4885 |
| US-20250263491-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | IGF1R 177/4885INSR 315/4885LYN 227/4885 |
| US-20230120736-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | IGF1R 4159/4885INSR 3877/4885LYN 3822/4885 |
| US-20250163159-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | IGF1R 99/4885INSR 412/4885LYN 243/4885 |
| US-20230077680-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | IGF1R 177/4885INSR 315/4885LYN 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.